{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:58:49Z","timestamp":1779346729578,"version":"3.51.4"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.msard.2018.04.014","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T22:23:07Z","timestamp":1524867787000},"page":"15-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-4566","authenticated-orcid":false,"given":"Konstantina G","family":"Yiannopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini I","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Siakantaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.04.014_bib0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.msard.2017.09.028","article-title":"Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment","volume":"18","author":"Baker","year":"2017","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"11","key":"10.1016\/j.msard.2018.04.014_bib0001","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"et al: CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.04.014_bib0002","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"9","key":"10.1016\/j.msard.2018.04.014_bib0003","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamaneurol.2017.1456","article-title":"Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab","volume":"74","author":"Gait\u00e1n","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2018.04.014_bib0005","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/leu.2009.146","article-title":"Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia","volume":"23","author":"\u00d6sterborg","year":"2009","journal-title":"Leukemia"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:14Z","timestamp":1761900074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":5,"alternative-id":["S2211034818301330"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.04.014","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}